Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(79 products)
- Syk(37 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1420 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TL13-110
CAS:<p>Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).</p>Formula:C49H62ClN9O9SColor and Shape:SolidMolecular weight:988.59MET/PDGFRA-IN-1
<p>MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.</p>Formula:C26H23N7OPurity:98%Color and Shape:SolidMolecular weight:449.51PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formula:C17H12F3N3O2Color and Shape:SoildMolecular weight:347.29Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formula:C41H74N2O20Color and Shape:SolidMolecular weight:915.028AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Formula:C17H14N6Purity:99.88%Color and Shape:SolidMolecular weight:302.33SNIPER(ABL)-024
CAS:<p>SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,</p>Formula:C52H61F3N8O9SPurity:98%Color and Shape:SolidMolecular weight:1031.15AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Color and Shape:Odour LiquidEGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Formula:C22H17F3N4OPurity:98%Color and Shape:SolidMolecular weight:410.39PROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formula:C40H46ClN11O5Purity:98%Color and Shape:SolidMolecular weight:796.32MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Formula:C52H72N12O11Purity:97.70%Color and Shape:SolidMolecular weight:1041.2DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Color and Shape:Odour SolidAD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurity:99.05%Color and Shape:SoildMolecular weight:455.44Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formula:C56H80N12O9SPurity:98%Color and Shape:SolidMolecular weight:1097.39EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Formula:C24H25BrN6O2Color and Shape:SolidMolecular weight:509.408ALK protein ligand-1
CAS:<p>ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.</p>Formula:C24H29ClN6O3SColor and Shape:SolidMolecular weight:517.043TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Color and Shape:Odour SolidBTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Color and Shape:Odour SolidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Formula:C26H20ClFN4OSColor and Shape:SolidMolecular weight:490.98EGFR-IN-86
<p>EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell</p>Formula:C20H21N7O2SPurity:98%Color and Shape:SolidMolecular weight:423.49MP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Color and Shape:Odour LiquidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formula:C20H17Cl2N3O3Color and Shape:SolidMolecular weight:418.273Lyn peptide inhibitor
CAS:<p>Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.</p>Formula:C115H184N30O24Purity:98%Color and Shape:SolidMolecular weight:2370.91FGFR1/VEGFR2-IN-1
<p>FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].</p>Formula:C26H27N4O6PPurity:98%Color and Shape:SolidMolecular weight:522.49ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Formula:C29H39ClN7O2PColor and Shape:SolidMolecular weight:584.1Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formula:C63H107N19O20S2Purity:98%Color and Shape:SolidMolecular weight:1514.77VEGFR-2-IN-66
<p>VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.</p>Color and Shape:Odour SolidCandidalysin
CAS:<p>Candidalysin is a cytolytic peptide toxin initially isolated from *Candida albicans*, exhibiting both toxic and non-toxic properties. It activates epithelial cell signaling pathways by interacting with the epithelial growth factor receptor (EGFR) on host cells, leading to the activation of matrix metalloproteinases (MMP) and calcium ion influx, which results in inflammatory responses and immune cell recruitment. Additionally, Candidalysin exhibits cytotoxicity by causing membrane damage to host cells.</p>Formula:C153H266N38O38S2Color and Shape:SolidMolecular weight:3310.11EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formula:C23H32BrN7O2SPurity:98%Color and Shape:SolidMolecular weight:550.51BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formula:C28H29FN6O2SColor and Shape:SolidMolecular weight:532.63Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Purity:95% - 95%Color and Shape:LiquidSA-VA
<p>SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.</p>Formula:C50H53ClF3N11O7SPurity:98%Color and Shape:SolidMolecular weight:1044.54Abicipar pegol
CAS:<p>Abicipar pegol is an anti-VEGF DARPin for ocular diseases, reducing retinal thickness and leakage.</p>Color and Shape:LiquidEGFR/BRAFV600E-IN-3
<p>EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.</p>Formula:C25H18N4O3Purity:98%Color and Shape:SolidMolecular weight:422.44Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formula:C33H34N4O3Color and Shape:SolidMolecular weight:534.648FAK-IN-27
<p>FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).</p>Formula:C32H28ClN5O6Color and Shape:SolidMolecular weight:613.17281Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Formula:C36H35ClN6O8S3Purity:98%Color and Shape:SolidMolecular weight:811.34EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formula:C20H17FN6O2S2Color and Shape:SolidMolecular weight:456.52JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formula:C30H33FN4O3SColor and Shape:SolidMolecular weight:548.67EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS:<p>Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.</p>Formula:C51H65N17O19P2S2·xC6H15NColor and Shape:SolidMolecular weight:1447.44RR-src
CAS:<p>Tyrosine kinase substrate peptide</p>Formula:C64H106N22O21Purity:98%Color and Shape:Lyophilized PowderMolecular weight:1519.66EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Formula:C17H15N7O5SColor and Shape:SolidMolecular weight:429.41EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Color and Shape:Odour SolidFGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Formula:C28H26Cl2N4O3Color and Shape:SolidMolecular weight:537.44MY-1576
<p>MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.</p>Formula:C25H29ClN8O2Color and Shape:SolidMolecular weight:509Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Color and Shape:Odour LiquidOK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Formula:C42H62N14O9Purity:98%Color and Shape:SolidMolecular weight:907.03Scr-IN-1
<p>Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.</p>Formula:C26H16ClF3N2O3Color and Shape:SolidMolecular weight:496.87MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Color and Shape:SolidMolecular weight:993.47FGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Formula:C36H42N12O6Color and Shape:SolidMolecular weight:738.33503
